REGULATORY PERSPECTIVES ON RISK-BASED MONITORING IN CLINICAL TRIALS OF HIGH-RISK MEDICAL DEVICES IN INDIA: A REVIEW

Clinical investigations of high-risk medical devices generate essential evidence for regulatory decisions concerning implanted, life-supporting, and potentially harmful devices. Traditional monitoring approaches, characterized by frequent on-site visits and extensive source data verification (SDV), are resource-intensive and may provide limited additional value in detecting critical errors. Risk-based monitoring (RBM), supported by risk-based quality management (RBQM), focuses monitoring activities on processes and data essential for participant safety and trial reliability. International regulatory bodies, including the International Council for Harmonisation (ICH), US Food and Drug Administration (FDA), European Medicines Agency (EMA), and International Organization for Standardization (ISO), support risk-proportionate quality management. In India, clinical investigations are governed by the Medical Devices Rules, 2017, administered by the Central Drugs Standard Control Organisation (CDSCO); however, dedicated provisions for RBM remain limited. This review examines global and Indian regulatory approaches to RBM in Class C and D medical device investigations. It discusses key components, including risk assessment, key risk indicators, quality tolerance limits, centralized monitoring, and targeted source data review. Published evidence regarding effectiveness, costs, and operational benefits is evaluated alongside device-specific challenges, implementation barriers, and emerging technologies such as electronic data capture, artificial intelligence, wearable sensors, and decentralized clinical trials. Traditional and risk-based monitoring approaches are compared, and a roadmap for integrating RBM into India's regulatory framework is proposed. RBM represents a scientifically justified and regulatorily supportable approach for high-risk medical device investigations, provided that a device-specific, CDSCO-aligned framework ensures documented risk assessment, proportionate monitoring, participant protection, data integrity, and auditable oversight.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-10-30
DOI
https://doi.org/10.5281/zenodo.23799316
Primary Topic
Healthcare Regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

REGULATORY PERSPECTIVES ON RISK-BASED MONITORING IN CLINICAL TRIALS OF HIGH-RISK MEDICAL DEVICES IN INDIA: A REVIEW

Divya Chugh, Aditya
Zenodo (CERN European Organization for Nuclear Research)
Healthcare Regulation
article

REGULATORY PERSPECTIVES ON RISK-BASED MONITORING IN CLINICAL TRIALS OF HIGH-RISK MEDICAL DEVICES IN INDIA: A REVIEW

Divya Chugh, Aditya
article en

Abstract

Clinical investigations of high-risk medical devices generate essential evidence for regulatory decisions concerning implanted, life-supporting, and potentially harmful devices. Traditional monitoring approaches, characterized by frequent on-site visits and extensive source data verification (SDV), are resource-intensive and may provide limited additional value in detecting critical errors. Risk-based monitoring (RBM), supported by risk-based quality management (RBQM), focuses monitoring activities on processes and data essential for participant safety and trial reliability. International regulatory bodies, including the International Council for Harmonisation (ICH), US Food and Drug Administration (FDA), European Medicines Agency (EMA), and International Organization for Standardization (ISO), support risk-proportionate quality management. In India, clinical investigations are governed by the Medical Devices Rules, 2017, administered by the Central Drugs Standard Control Organisation (CDSCO); however, dedicated provisions for RBM remain limited. This review examines global and Indian regulatory approaches to RBM in Class C and D medical device investigations. It discusses key components, including risk assessment, key risk indicators, quality tolerance limits, centralized monitoring, and targeted source data review. Published evidence regarding effectiveness, costs, and operational benefits is evaluated alongside device-specific challenges, implementation barriers, and emerging technologies such as electronic data capture, artificial intelligence, wearable sensors, and decentralized clinical trials. Traditional and risk-based monitoring approaches are compared, and a roadmap for integrating RBM into India's regulatory framework is proposed. RBM represents a scientifically justified and regulatorily supportable approach for high-risk medical device investigations, provided that a device-specific, CDSCO-aligned framework ensures documented risk assessment, proportionate monitoring, participant protection, data integrity, and auditable oversight.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being, Industry, innovation and infrastructure
Openalex Percentile: Top 8%
Healthcare Regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
REGULATORY PERSPECTIVES ON RISK-BASED MONITORING IN CLINICAL TRIALS OF HIGH-RISK MEDICAL DEVICES IN INDIA: A REVIEW — Divya Chugh, Aditya · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS